Faron Pharmaceuticals Oy (FPHAF) Stock

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical firm dedicated to drug discovery and development. The company is advancing a pipeline of proprietary drug candidates that harness immune modulation to address significant unmet medical needs, spanning immuno-oncology, organ protection, and regenerative medicine. Its principal product candidates include Traumakine, an intravenous interferon beta-1a therapy, which targets acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant procedures, and ischemia-reperfusion injury. Additionally, Bexmarilimab stands as a significant candidate, representing a novel precision immunotherapy for various cancers, such as solid tumors, non-small cell lung carcinoma, and hematological malignancies. Faron also has Haematokine in development, a new chemical entity and AOC3 inhibitor designed to treat hematological malignancies and bone marrow conditions. Established in 2003, Faron Pharmaceuticals Oy maintains its headquarters in Turku, Finland.

Faron Pharmaceuticals Oy is headquartered in FI.

Faron Pharmaceuticals Oy (FPHAF) stock trades at $3.30 with a market capitalization of $209.54M. The stock is valued at a price-to-earnings (P/E) ratio of -2.96, price-to-book of -2.84, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.30 and $3.30, and currently trades at its 52-week high.

On profitability, Faron Pharmaceuticals Oy generates a return on equity (ROE) of 45.13% — well above the market average, a sign of a high-quality business, return on capital employed of 491.36%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.faron.com